|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Denisenko TV, Budkevich IN and Zhivotovsky
B: Cell death-based treatment of lung adenocarcinoma. Cell Death
Dis. 9:1172018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu Y, Wang Z, Zheng Q and Li J: FAM72
serves as a biomarker of poor prognosis in human lung
adenocarcinoma. Aging (Albany NY). 13:8155–8176. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang C, Tan S, Liu WR, Lei Q, Qiao W, Wu
Y, Liu X, Cheng W, Wei YQ, Peng Y and Li W: RNA-Seq profiling of
circular RNA in human lung adenocarcinoma and squamous cell
carcinoma. Mol Cancer. 18:1342019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li Y, Yu X, Zhang Y, Wang X, Zhao L, Liu
D, Zhao G, Gao X, Fu J, Zang A and Jia Y: Identification of a novel
prognosis-associated ceRNA network in lung adenocarcinoma via
bioinformatics analysis. Biomed Eng Online. 20:1172021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li H, Guo L and Cai Z: TCN1 is a potential
prognostic biomarker and correlates with immune infiltrates in lung
adenocarcinoma. World J Surg Oncol. 20:832022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yuanhua L, Pudong Q, Wei Z, Yuan W, Delin
L, Yan Z, Geyu L and Bo S: TFAP2A Induced KRT16 as an Oncogene in
Lung Adenocarcinoma via EMT. Int J Biol Sci. 15:1419–1428. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu ZP: Reverse engineering of genome-wide
gene regulatory networks from gene expression data. Curr Genomics.
16:3–22. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Langfelder P and Horvath S: WGCNA: An R
package for weighted correlation network analysis. BMC
Bioinformatics. 9:5592008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu Z, Li M, Fang X, Shen L, Yao W, Fang
Z, Chen J, Feng X, Hu L, Zeng Z, et al: Identification of surrogate
prognostic biomarkers for allergic asthma in nasal epithelial
brushing samples by WGCNA. J Cell Biochemi. 120:5137–5150. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dong S, Men W, Yang S and Xu S:
Identification of lung adenocarcinoma biomarkers based on
bioinformatic analysis and human samples. Oncol Rep. 43:1437–1450.
2020.PubMed/NCBI
|
|
12
|
Zhang L, He M, Zhu W, Lv X, Zhao Y, Yan Y,
Li X, Jiang L, Zhao L, Fan Y, et al: Identification of a panel of
mitotic spindle-related genes as a signature predicting survival in
lung adenocarcinoma. J Cell Physiol. 235:4361–4375. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang L, Li S, Wang Y, Tang Z, Liu C, Jiao
W and Liu J: Identification of differentially expressed
protein-coding genes in lung adenocarcinomas. Exp Ther Med.
19:1103–1111. 2020.PubMed/NCBI
|
|
14
|
Li J, Liu X, Cui Z and Han G:
Comprehensive analysis of candidate diagnostic and prognostic
biomarkers associated with lung adenocarcinoma. Med Sci Monit.
26:e9220702020.PubMed/NCBI
|
|
15
|
Wang Y, Zhou Z, Chen L, Li Y, Zhou Z and
Chu X: Identification of key genes and biological pathways in lung
adenocarcinoma via bioinformatics analysis. Mol Cell Biochem.
476:931–939. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen C, Tang Y, Qu WD, Han X, Zuo JB, Cai
QY, Xu G, Song YX and Ke XX: Evaluation of clinical value and
potential mechanism of MTFR2 in lung adenocarcinoma via
bioinformatics. BMC Cancer. 21:6192021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fan X, Wang Y and Tang XQ: Extracting
predictors for lung adenocarcinoma based on Granger causality test
and stepwise character selection. BMC Bioinformatics. 20 (Suppl
7):S1972019. View Article : Google Scholar
|
|
18
|
Guo W, Sun S, Guo L, Song P, Xue X, Zhang
H, Zhang G, Wang Z, Qiu B, Tan F, et al: Elevated TOP2A and UBE2C
expressions correlate with poor prognosis in patients with
surgically resected lung adenocarcinoma: A study based on
immunohistochemical analysis and bioinformatics. J Cancer Res Clin
Oncol. 146:821–841. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Du R, Huang C, Liu K, Li X and Dong Z:
Targeting AURKA in Cancer: Molecular mechanisms and opportunities
for Cancer therapy. Mol Cancer. 20:152021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Meng J, Wei Y, Deng Q, Li L and Li X:
Study on the expression of TOP2A in hepatocellular carcinoma and
its relationship with patient prognosis. Cancer Cell Int.
22:292022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Yang H, Wang L, Zhou H, Zhang G,
Xiao Z and Xue X: TOP2A correlates with poor prognosis and affects
radioresistance of medulloblastoma. Front Oncol. 12:9189592022.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang F and Wu H: MiR-599 targeting TOP2A
inhibits the malignancy of bladder cancer cells. Biochem Biophys
Res Commun. 570:154–161. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gao Y, Zhao H, Ren M, Chen Q, Li J, Li Z,
Yin C and Yue W: TOP2A promotes tumorigenesis of high-grade serous
ovarian cancer by regulating the TGF-β/Smad pathway. J Cancer.
11:4181–4192. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang B, Shen Y, Zou Y, Qi Z, Huang G, Xia
S, Gao R, Li F and Huang Z: TOP2A promotes cell migration, invasion
and epithelial-mesenchymal transition in cervical cancer via
activating the PI3K/AKT signaling. Cancer Manag Res. 12:3807–3814.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pei YF, Yin XM and Liu XQ: TOP2A induces
malignant character of pancreatic cancer through activating
β-catenin signaling pathway. Biochim Biophys Acta Mol Basis Dis.
1864:197–207. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen YU, Yu Y, Lv M, Shi Q and Li X:
E2F1-mediated up-regulation of TOP2A promotes viability, migration,
and invasion, and inhibits apoptosis of gastric cancer cells. J
Biosci. 47:842022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Du X, Xue Z, Lv J and Wang H: Expression
of the topoisomerase II alpha (TOP2A) gene in lung adenocarcinoma
cells and the association with patient outcomes. Med Sci Monit.
26:e9291202020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen C, Guo Q, Song Y, Xu G and Liu L:
SKA1/2/3 serves as a biomarker for poor prognosis in human lung
adenocarcinoma. Transl Lung Cancer Res. 9:218–231. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gray D, Jubb AM, Hogue D, Dowd P, Kljavin
N, Yi S, Bai W, Frantz G, Zhang Z, Koeppen H, et al: Maternal
embryonic leucine zipper kinase/murine protein serine-threonine
kinase 38 is a promising therapeutic target for multiple cancers.
Cancer Res. 65:9751–9761. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li Y, Li Y, Chen Y, Xie Q, Dong N, Gao Y,
Deng H, Lu C and Wang S: MicroRNA-214-3p inhibits proliferation and
cell cycle progression by targeting MELK in hepatocellular
carcinoma and correlates cancer prognosis. Cancer Cell Int.
17:1022017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen S, Zhou Q, Guo Z, Wang Y, Wang L, Liu
X, Lu M, Ju L, Xiao Y and Wang X: Inhibition of MELK produces
potential anti-tumour effects in bladder cancer by inducing G1/S
cell cycle arrest via the ATM/CHK2/p53 pathway. J Cell Mol Med.
24:1804–1821. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cancer Genome Atlas Research Network, .
Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA,
Ellrott K, Shmulevich I, Sander C and Stuart JM: The Cancer Genome
Atlas Pan-Cancer analysis project. Nat Genet. 45:1113–1120. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Allemani C, Matsuda T, Di Carlo V,
Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ,
Estève J, et al: Global surveillance of trends in cancer survival
2000–14 (CONCORD-3): Analysis of individual records for 37 513 025
patients diagnosed with one of 18 cancers from 322 population-based
registries in 71 countries. Lancet. 391:1023–1075. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao X, Zhang L, Wang J, Zhang M, Song Z,
Ni B and You Y: Identification of key biomarkers and immune
infiltration in systemic lupus erythematosus by integrated
bioinformatics analysis. J Transl Med. 19:352021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hu X, Bao M, Huang J, Zhou L and Zheng S:
Identification and validation of novel biomarkers for diagnosis and
prognosis of hepatocellular carcinoma. Front Oncol. 10:5414792020.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang Q, Wang R, Wei B, Peng C, Wang L, Hu
G, Kong D and Du C: Candidate biomarkers and molecular mechanism
investigation for glioblastoma multiforme utilizing WGCNA. Biomed
Res Int. 2018:42467032018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vernocchi P, Gili T, Conte F, Del Chierico
F, Conta G, Miccheli A, Botticelli A, Paci P, Caldarelli G, Nuti M,
et al: Network analysis of gut microbiome and metabolome to
discover microbiota-linked biomarkers in patients affected by
non-small cell lung cancer. Int J Mol Sci. 21:87302020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Otto T and Sicinski P: Cell cycle proteins
as promising targets in cancer therapy. Nat Rev Cancer. 17:93–115.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li Z, Zhang Y, Zhou Y, Wang F, Yin C, Ding
L and Zhang S: Tanshinone IIA suppresses the progression of lung
adenocarcinoma through regulating CCNA2-CDK2 complex and AURKA/PLK1
pathway. Sci Rep. 11:236812021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhong N, Shi S, Wang H, Wu G, Wang Y, Ma
Q, Wang H, Liu Y and Wang J: Silencing Aurora-A with siRNA inhibits
cell proliferation in human lung adenocarcinoma cells. Int J Oncol.
49:1028–1038. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang MY, Liu XX, Li H, Li R, Liu X and Qu
YQ: Elevated mRNA Levels of AURKA, CDC20 and TPX2 are associated
with poor prognosis of smoking related lung adenocarcinoma using
bioinformatics analysis. Int J Med Sci. 15:1676–1685. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang PJ, Hsieh MJ, Lee CI, Yen CH, Wang
HL, Chiang WL, Liu TC, Tsao TC, Lee CY and Yang SF: Impact of
aurora kinase a polymorphism and epithelial growth factor receptor
mutations on the clinicopathological characteristics of lung
adenocarcinoma. Int J Environ Res Public Health. 17:73502020.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zheng X, Chi J, Zhi J, Zhang H, Yue D,
Zhao J, Li D, Li Y, Gao M and Guo J: Aurora-A-mediated
phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to
facilitate NSCLC growth and migration. Oncogene. 37:502–511. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shah KN, Bhatt R, Rotow J, Rohrberg J,
Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, et al:
Aurora kinase A drives the evolution of resistance to
third-generation EGFR inhibitors in lung cancer. Nat Med.
25:111–118. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gao J, Lu F, Yan J, Wang R, Xia Y, Wang L,
Li L, Chang L and Li W: The role of radiotherapy-related autophagy
genes in the prognosis and immune infiltration in lung
adenocarcinoma. Front Immunol. 13:9926262022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Grenda A, Błach J, Szczyrek M, Krawczyk P,
Nicoś M, Kuźnar Kamińska B, Jakimiec M, Balicka G, Chmielewska I,
Batura-Gun H, et al: Promoter polymorphisms of TOP2A and ERCC1
genes as predictive factors for chemotherapy in non-small cell lung
cancer patients. Cancer Med. 9:605–614. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kou F, Sun H, Wu L, Li B, Zhang B, Wang X
and Yang L: TOP2A promotes lung adenocarcinoma cells' malignant
progression and predicts poor prognosis in lung adenocarcinoma. J
Cancer. 11:2496–2508. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zeng H, Ji J, Song X, Huang Y, Li H, Huang
J and Ma X: Stemness related genes revealed by network analysis
associated with tumor immune microenvironment and the clinical
outcome in lung adenocarcinoma. Front Genet. 11:5492132020.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Song Y, Tang W and Li H: Identification of
KIF4A and its effect on the progression of lung adenocarcinoma
based on the bioinformatics analysis. Biosci Rep.
41:BSR202039732021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Dai JJ, Zhou WB and Wang B: Identification
of crucial genes associated with lung adenocarcinoma by
bioinformatic analysis. Medicine (Baltimore). 99:e230522020.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang S, Pang K, Feng X and Zeng Y:
Transcriptomic data exploration of consensus genes and molecular
mechanisms between chronic obstructive pulmonary disease and lung
adenocarcinoma. Sci Rep. 12:132142022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Deng Y, Chen X, Huang C, Song J, Feng S,
Chen X and Zhou R: Screening and validation of significant genes
with poor prognosis in pathologic Stage-I lung adenocarcinoma. J
Oncol. 2022:37940212022. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yin J, Che G, Jiang K, Zhou Z, Wu L, Xu M,
Liu J and Yan S: Ciclopirox olamine exerts tumor-suppressor effects
via topoisomerase II alpha in lung adenocarcinoma. Front Oncol.
12:7919162022. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhang YQ, Li K, Guo Q and Li D: A new risk
model based on 7 quercetin-related target genes for predicting the
prognosis of patients with lung adenocarcinoma. Front Genet.
13:8900792022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Du T, Qu Y, Li J, Li H, Su L, Zhou Q, Yan
M, Li C, Zhu Z and Liu B: Maternal embryonic leucine zipper kinase
enhances gastric cancer progression via the FAK/Paxillin pathway.
Mol Cancer. 13:1002014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
McDonald IM and Graves LM: Enigmatic MELK:
The controversy surrounding its complex role in cancer. J Biol
Chem. 295:8195–8203. 2020. View Article : Google Scholar : PubMed/NCBI
|
